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T
he Battle of Trafalgar was a 
short-lasting but bloody affair. 
By the end of the afternoon 
of 21 October 1805, the French/
Spanish ﬂ  eet had lost 4,408 men, and 
a further 2,545 were wounded while 
the victorious British force suffered 
455 dead and 1,242 wounded [1]. 
The British ﬂ  agship HMS Victory, 
where Admiral Horatio Nelson lost 
his life to a sniper’s bullet, sustained 
56 other deaths. The surgeon on 
board, Dr. William Beatty, also listed 
102 wounded sailors who survived 
the battle or its immediate aftermath 
[2]. He needed to perform ten 
amputations, mainly involving the leg, 
and reported instances of death from 
gangrene and tetanus. Yet only six of 
the 102 wounded sailors subsequently 
died. 
This remarkably low mortality rate 
was mirrored by that sustained by the 
13th Light Dragoons during the Battle 
of Waterloo in 1815. Of 52 privates 
reported as wounded, only three later 
died of their wounds [3]. 
The United States Civil War ﬁ  ve 
decades later was a more protracted 
but equally bitter conﬂ  ict, with over 
550,000 deaths in the four years of 
battle [4]. Of note, twice as many 
troops died from disease, privation, 
and accidents than died of injuries 
sustained on the battleﬁ  eld. Typhus, 
typhoid fever, mumps, and measles 
were rife in army camps where poor 
sanitation, hygiene, and an inadequate 
diet were the norm. The surgeons 
in these camps often held their 
instruments between their teeth, 
and these tools were only cleaned 
at the end of the day’s operating. At 
the Battle of Antietam, maize husks 
were used as bandages. Yet despite 
the prevailing conditions and lack of 
aseptic technique, mortality rates were 
remarkably good. The Union forces 
kept detailed records and reported a 
directly attributable mortality rate from 
battleﬁ  eld injuries of 14%. The overall 
mortality rate following amputation was 
only about 25%, (Table 1) with some 
patients even surviving hindquarter 
amputation [5]. 
Then and Now
These survival rates do appear 
impressive, especially when one 
considers that they were obtained 
without antisepsis, antibiotics, blood 
transfusion, oxygen, and the other 
paraphernalia of modern medicine, 
and that the surgeons relied upon 
rudimentary surgical techniques 
performed without the assistance or 
comforts of sophisticated anaesthesia 
or mechanical ventilation. 
Clearly, a direct analogy should 
not be made to the mortality rates 
for today’s battleﬁ  eld injuries, which 
involve far more destructive weaponry, 
or to those of modern hospital 
populations, where many patients are 
elderly and/or immunosuppressed. 
Nevertheless, it is valid to wonder why 
even greater improvements in outcome 
have not been achieved in the last 
two to three decades despite the huge 
advances made in medical technology, 
treatments, and understanding of 
underlying pathological mechanisms. 
Barring the 1919 inﬂ  uenza pandemic, 
Armstrong et al. reported an impressive 
22-fold fall in crude mortality rates for 
infectious diseases in the US between 
1900 and 1980 [6]. Yet they also 
showed how mortality rates (to 1996) 
have since increased—by 50%—with 
the septicaemia rate nearly doubling. 
While it is true that people are 
living longer, with an increase in life 
expectancy from 1980 to 1996 of 2.4 
years (from 73.7 to 76.1) [7], these 
gains are unlikely to be due to advances 
in hospital medicine. They are far more 
likely to be due to the contribution of 
better public health and education, 
including reductions in environmental 
pollution, altered eating and smoking 
habits, and increased exercise.
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Table 1. Mortality Rates from Amputations During the US Civil War 
Amputation Type Cases Deaths Percentage Deaths
Fingers  7,902  198  2.5
Forearms  1,761  245   13.9
Upper arms   5,540   1,273  23.0
Toes   1,519   81   5.3
Legs  5,523   1,790   32.4
Amputation at thigh   6,369   3,411  53.6
Amputation at knee joint   195   111  56.9
Amputation at hip joint   66   55  83.3
Amputation at ankle   161   119  73.9
Total  29,980  7,283  24.3%
Data are taken from [5]
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The Poor Evidence Base for Many 
Interventions
An important but generally overlooked 
consideration is the possibility that 
superﬁ  cially attractive, short-term 
beneﬁ  ts may camouﬂ  age an underlying 
tendency to cause harm. There are 
high-proﬁ  le instances where injury 
is belatedly recognised. A recent 
example is the increased risk in 
serious cardiovascular thrombotic 
events seen in patients taking the 
anti-inﬂ  ammatory COX II inhibitor 
rofecoxib [8]. Clearly, some individuals 
have suffered, yet the target patient 
group as a whole has been protected by 
the much greater surveillance given to 
a new pharmaceutical compound and 
the improved likelihood of detecting 
a major complication. How many 
long-standing medications, devices, 
or treatment regimens have been 
scrutinised to a remotely similar extent? 
A fundamental tenet of medical 
teaching is to ﬁ  rst do no harm to 
our patients. Every decision affecting 
patient management should thus be 
judged on the basis of the ratio of likely 
risks to beneﬁ  ts. Alas, large chunks 
of perceived wisdom rely on expert 
opinion, historical practice, and blind 
acceptance, rather than on an adequate 
evidence base, to vindicate continued 
use of a drug, device, or management 
strategy. 
For example, more than half the 
50-plus recommendations made in 
the recent Surviving Sepsis guidelines 
[9], which have been endorsed and 
are now being heavily promoted by 
the US and European critical care 
societies as a standard of care, were 
based solely on expert opinion. Many 
of the other, more highly graded, 
recommendations relied upon studies 
with small patient numbers and/or 
methodological ﬂ  aws. Of only four 
Grade A recommendations (i.e., 
those supported by at least two large, 
randomised trials with clear-cut results), 
deep vein thrombosis prophylaxis and 
ventilator weaning are generic issues 
for all critically ill patients, while the 
other two (avoidance of high-dose 
corticosteroids, and not striving to 
achieve speciﬁ  ed target values of 
oxygen delivery/consumption when 
resuscitating patients with ﬂ  uids and 
inotropes) were based upon studies 
performed over a decade ago. The 
two latter recommendations arose 
from “negative” studies 
in which the standards 
of care at the time were 
shown to be ineffective 
[10] or even harmful 
[11]. This recognition 
of harm also applies 
to many of the Grade 
B recommendations 
(i.e., supported by 
one large, randomised 
trial), for example, 
the lower threshold of 
haemoglobin used to 
trigger blood transfusion 
[12], or the reduced tidal 
volumes delivered during 
mechanical ventilation 
[13]. 
Fashionable 
Treatments for Critical 
Illness: Are They 
Harming Patients?
The major advances of 
intensive care medicine 
in the last 20 years have 
been related more to the 
recognition and removal 
of harmful practices 
rather than to any 
novel pharmacological or mechanical 
interventions. It is thus reasonable 
to question how many currently 
fashionable strategies may actually 
prove injurious when submitted to 
critical examination (Table 2)? This 
assumes, of course, that the inclination 
to challenge dogma exists. 
A perfect example of this unwavering 
adherence to an article of faith is the 
ﬂ  awed reliance upon furosemide as 
ﬁ  rst-line therapy in the management 
of patients with acute heart failure. 
Such patients rarely have intravascular 
volume overload, yet they are often 
given a potent loop diuretic, which 
will frequently result in hypovolaemia, 
vasoconstriction, increased ventricular 
strain, and a decrease in cardiac output 
[14]. This effect is not apparent at the 
end of the needle, where the initial 
but short-lived vasodilatation produces 
symptomatic relief and a transient 
improvement in haemodynamics. 
Thus, it is highly convenient to blame 
the patient’s failing heart for any 
subsequent deterioration without 
recognition and acceptance of any 
iatrogenic component. 
Recent European Society of 
Cardiology guidelines for the 
management of acute heart failure 
[15] make repeated references to the 
harmful consequences of diuretic 
use, emphasising that “secondary 
effects are frequent and may be life-
threatening.” Yet the Task Force of 
experts still proceeded to make a Class 
I recommendation for their continued 
use (i.e., evidence and/or general 
agreement that a given diagnostic 
procedure/treatment is beneﬁ  cial, 
useful, and effective), with a “B” level 
of evidence (i.e., data derived from 
a single, randomised clinical trial or 
large, nonrandomised studies). Their 
justiﬁ  cation for this grading—which 
was not actually underpinned by any 
trial data, either large or randomised—
was that “The symptomatic beneﬁ  ts (of 
diuretics) and their universal clinical 
acceptance have precluded a formal 
evaluation in large-scale randomised 
clinical trials.” Indeed, the single 
prospective randomised outcome 
study performed to date (and cited by 
the guidelines) actually showed the 
superiority of nitrates over furosemide 
[16].
The key phrase used above is 
“universal clinical acceptance”—that 
is to say, “we believe diuretics work, 
DOI: 10.1371/journal.pmed.0020167.g001
Figure 1. Hypothesis Explaining the Pathophysiology of Multiple 
Organ Failure Following Infection and Other Inﬂ  ammatory Insults
Antibiotics, sedatives, and inotropes may cause harm 
through inhibition of mitochondrial function. Antibiotics 
may also delay recovery by impeding mitochondrial 
regeneration.
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as we’ve used them unquestioningly 
throughout our medical careers, 
so we can’t possibly question this 
particular shibboleth in a critically 
objective fashion.” Has there been any 
consideration of the possibility that the 
long-term outcome beneﬁ  ts derived 
from ACE inhibitors may be, at least in 
part, related to the necessary decrease 
in diuretic dosing?
In more severe heart failure and 
other forms of shock associated with 
low blood pressures and/or low 
cardiac outputs, there is a conventional 
reliance upon catecholamines such 
as dobutamine, norepinephrine, and 
epinephrine. Yet these inotrope and 
pressor agents have many effects distant 
from their cardiovascular actions. 
They have metabolic effects including 
increased ß-oxidation of fats; they are 
pro-arrhythmogenic; they have pro- and 
anti-inﬂ  ammatory effects; and they can 
alter both immunity and mitochondrial 
function [17–21]. Lyte et al. showed 
that the use of catecholamine inotropes 
was associated with signiﬁ  cant increases 
in bacterial growth of Gram-positive 
[22] and Gram-negative [23] bacteria 
and in the formation of bioﬁ  lms [22]. 
Indeed, all large randomised 
studies performed to date in patients 
with chronic heart failure that 
have compared catecholamines or 
phosphodiesterase inhibitors (both 
of which increase cyclic adenosine 
monophosphate [AMP] levels) against 
either placebo or another treatment 
have also shown detriment. Even 
short-term (1–2 day) infusions of the 
phosphodiesterase inhibitors milrinone 
and vesnanrinone signiﬁ  cantly 
worsened six-month outcomes [24,25]. 
A similar effect has been reported 
with dobutamine in comparison to 
the calcium sensitiser levosimendan 
[26,27]. 
Intensive care physicians also use 
antibiotics, sedatives, inotropes, and 
blood products extensively. While 
necessary in many cases, there is 
an increasingly strong feeling that 
these agents are being overused, as 
many problems and complications 
are directly attributable to them. For 
example, excessive antibiotic use is 
related to the development of bacterial 
resistance and fungal overgrowth 
[28], while overuse of sedatives delays 
weaning from mechanical ventilation 
[29]. However, less consideration is 
paid to other effects of these drugs that 
could arguably be just as injurious, if 
not more so. 
Underlying Mechanisms for Why 
Our Treatments May Cause Harm
How can we explain, at the molecular 
level, the covert harm to the 
patient from standard drugs such as 
antibiotics, sedatives, and inotropes? 
The answer may lie in understanding 
the pathophysiological mechanisms 
underlying multiple organ failure, 
such as changes in immune and 
hormonal status and the role of the 
mitochondrion.
Over a billion years ago, a bacterium 
containing the oxygen-consuming 
respiratory chain is likely to have 
invaded the early eukaryotic cell. Most 
of the bacterial genetic information 
was subsequently transferred to the 
nucleus, transforming these bacterial 
symbionts into “slave” mitochondrial 
organelles. This provided a far more 
efﬁ  cient system for using available 
energy sources and also protected 
the cell against the potentially toxic 
effects of oxygen. More than 90% of 
total body oxygen consumption is used 
to generate adenosine triphosphate 
(ATP) by the mitochondrial electron 
transport chain, and this, in turn, 
provides more than 90% of the body’s 
power, the remainder coming from 
glycolysis. 
An attractive hypothesis to explain 
the pathophysiology of multiple organ 
failure following infection and other 
inﬂ  ammatory insults is a mitochondrial 
shutdown leading to “energy failure” 
and a consequent inability to drive 
the various metabolic processes that 
maintain normal cellular functioning 
(Figure 1). Inﬂ  ammatory mediators 
released in considerable excess in 
sepsis, such as tumor necrosis factor 
and nitric oxide, are known to directly 
inhibit mitochondrial respiration. 
We and others have demonstrated 
this mechanism in septic patients and 
laboratory models [30–32]. The down-
regulation of endocrine function seen 
in established sepsis, for example, 
the sick euthyroid syndrome, insulin 
resistance, and hypoleptinaemia, will 
also impinge on mitochondrial activity 
[33]. If the cell attempts to continue to 
function normally despite inadequate 
energy production, the resulting fall 
in adenosine triphosphate will trigger 
necrotic and apoptotic death pathways. 
However, as this process is not 
immediate (it takes hours to days to 
develop fully) the cell has time to 
potentially adapt to this prolonged, 
life-threatening insult. It is likely to 
do so by entering a hibernation-like 
state. The impressive and almost total 
absence of cell death seen in organs 
that have “failed” biochemically and/or 
physiologically [34] lends credence to 
this hypothesis. Restoration of cellular 
function, and thus recovery from 
organ failure, must therefore depend 
upon repair of damaged mitochondria 
and/or production of new organelles, 
a process known as mitochondrial 
biogenesis.
Harm from Antibiotics 
The reason for this preamble is to 
emphasise the role of the systemic 
inﬂ  ammatory response and the likely 
fundamental importance of the 
mitochondrion in the development 
of multiple organ failure, and also the 
Table 2. Examples of Fashionable Treatments for Critical Illness That May Cause Harm
Treatment Harmful Effects
Furosemide as ﬁ  rst-line therapy for acute heart 
failure
Hypovolaemia, vasoconstriction, increased ventricular strain, 
increased sympathetic activation and a decrease in cardiac 
output [14]
Catecholamines for severe heart failure and other 
forms of shock
Increased ß-oxidation of fats, pro-arrhythmogenic, pro- 
and anti-inﬂ  ammatory effects, altered immunity and 
mitochondrial function [17–21, increased bacterial growth 
[22,23]
Antibiotics Endotoxin release from Gram-negative bacteria [35,36] and 
lipoteichoic acid and peptidoglycan release from Gram-
positive bacteria [37,38], leading to increased inﬂ  ammatory 
mediator production; altered mitochondrial function
Sedatives Altered mitochondrial function [43–48], altered immune 
function and immunosuppression [49–56], adrenal 
suppression [57,58]
DOI: 10.1371/journal.pmed.0020167.t002
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mitochondrion’s distant lineage but 
existing genetic linkage to bacteria. 
We use antibiotics to ﬁ  ght bacteria, 
and they are undoubtedly successful in 
many instances. Many of the antibiotic 
classes, such as the penicillins and 
cephalosporins, are bactericidal 
through cell-wall disruption, whereas 
other classes, such as chloramphenicol 
and aminoglycosides, act in a 
bacteriostatic manner by inhibiting 
protein synthesis. However, by virtue of 
their action, the cell-wall disrupters—in 
particular the cephalosporins—cause 
increased levels of endotoxin 
release from Gram-negative bacteria 
[35,36] and lipoteichoic acid and 
peptidoglycan release from Gram-
positive bacteria [37,38]. This 
enhanced toxin release leads to 
signiﬁ  cantly higher inﬂ  ammatory 
mediator production. This may well 
explain the rapid clinical deterioration 
often seen in patients with sepsis 
after the ﬁ  rst dose of cidal antibiotics, 
though long-term consequences 
remain unknown. 
A delayed and potentially 
signiﬁ  cant effect of antibiotics may 
be seen through their inhibition of 
mitochondrial activity and biogenesis. 
This inhibition has been shown in 
numerous in vitro studies, in which 
cell lines or isolated mitochondria 
have been incubated with antibiotics 
at concentrations equivalent to 
therapeutic blood levels. Signiﬁ  cant 
decreases in respiratory enzyme activity 
and protein turnover have been found 
across a wide range of antibiotic classes 
[39–42]. Could our antibiotic therapy 
be thus accentuating the degree of 
sepsis and multiple organ dysfunction 
through increased inﬂ  ammatory 
mediator release and mitochondrial 
depression? Could such therapy also 
be delaying recovery by impeding 
mitochondrial regeneration? 
Harm from Sedatives
Continuing on this theme, the 
major classes of sedative/anesthetic 
agents (opiates, benzodiazepines, 
propofol, barbiturates, and volatile 
anaesthetic agents) routinely used to 
enable mechanical ventilation in the 
operating theatre or intensive care 
unit all have effects on mitochondrial 
function in vitro [43–48]. In the case 
of propofol, these effects appear to be 
signiﬁ  cantly enhanced in the presence 
of nitric oxide through formation of 
nitrosopropofol [45]. Thus, sepsis 
may potentially amplify the effects of 
this sedative agent on mitochondrial 
inhibition. This mechanism may 
explain the severe metabolic and 
physiological deterioration reported in 
children and adults receiving propofol 
[48]. 
All classes of sedative agents have 
also been shown to alter immune 
function in neutrophils, monocytes, 
and lymphocytes in vitro and to 
affect rates of apoptosis [49–54]. 
Immunosuppression (for example, 
assessed in monocytes by HLA-DR 
status) is well recognised in established 
sepsis and is related to worse outcomes 
[55,56]. The clinical signiﬁ  cance of 
sedative drug actions on the immune 
response to critical illness remains 
unknown.
Certain sedatives are also known 
to affect hormonal status. The most 
striking example is the classic study 
by Watt and Ledingham, who sought 
an explanation for the sudden jump 
in mortality rates in their critically ill 
trauma patients: from 28% in those 
receiving opiates and benzodiazepines 
to 77% of those sedated with etomidate 
[57]. They showed a signiﬁ  cant 
etomidate-induced depression of 
adrenal function that led to withdrawal 
of its use for medium- to long-term 
sedation in intensive care. Etomidate 
is, however, still frequently used as 
an induction agent for anaesthesia 
because of its cardiovascular stability. 
Unfortunately, this practice continues 
despite the fact that Absalom et al. have 
shown that a single dose of etomidate 
given before surgery in critically ill 
patients was sufﬁ  cient to compromise 
adrenal function 24 hours later [58]. 
Harm from Other Drugs and 
Interventions
Other drugs are known to affect 
hormone levels. Low-dose dopamine, 
which was a popular and subsequently 
disproved therapy for maintaining 
renal function, rapidly reduces serum 
prolactin levels [59]. Prolactin has 
immunostimulatory effects, and a low 
prolactin level has been associated with 
a worse outcome in septic mice [60]. 
The recognition that impaired adrenal 
function, as assessed by a subnormal 
rise in plasma cortisol to synthetic 
adrenocorticotropic hormone, was 
related to poor outcomes in septic 
shock [61] led to a multicentre trial 
that revealed survival beneﬁ  t from 
early administration of hydrocortisone 
50 mg four times daily [62]. However, 
the debate continues surrounding 
its contribution to the development 
of critical illness neuromyopathy 
and delayed weaning [63]. The 
sick euthyroid syndrome is likewise 
associated with worse outcomes [64] 
yet several drugs that affect thyroid 
function, such as amiodarone, are 
frequently used in critically ill patients. 
These concerns can be replicated 
across virtually every therapy area in the 
critically ill.
Mechanical ventilation. A strategy of 
delivering low tidal volumes rather than 
the previously fashionable high tidal 
volumes during mechanical ventilation 
reduced mortality from 39% to 31% 
[13]; this change in strategy has been 
separately shown to also reduce both 
the local and systemic inﬂ  ammatory 
response, presumably from lowering 
shear stresses within the lung [65]. 
Immunonutrition. A trial of 
immunonutrition had to be prematurely 
terminated after an interim analysis 
revealed a signiﬁ  cant mortality increase 
in septic patients [66]. 
Drotrecogin-alpha. The Canadian 
Department of Health recently issued 
a safety alert on Drotrecogin-alpha 
(Xigris), the ﬁ  rst licensed therapy for 
severe sepsis, after post-hoc analyses 
of trial data revealed an excess 
mortality in patients with single organ 
dysfunction who had received surgery 
within 30 days prior to study treatment 
[67].
Blood transfusion. Lowering the 
threshold for blood transfusion from 
10 g/dl to 7 g/dl, and thus reducing 
transfusion requirements from an 
average of 5.6 ± 5.3 red-cell units per 
patient to 2.6 ± 4.1 units, reduced 
30-day mortality rates from 23.3% to 
18.7% [12]. In a recent retrospective 
analysis of three large trials of patients 
with acute coronary syndromes, Rao et 
al. reported a 3-fold increase in death 
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and myocardial infarction rates in those 
who received a blood transfusion [68]. 
There may be an immunological reason 
underlying this apparent harm. Hebert 
et al. found signiﬁ  cant reductions 
in mortality rates, post-transfusion 
fevers, and antibiotic use in patients 
who received leukoreduced blood 
transfusions, compared to historical 
controls who received “normal” blood 
[69]. It remains to be seen whether 
remaining blood constituents in 
leukocyte-depleted blood are able to 
also affect the immune response. 
Proton pump inhibitors. A recent 
meta-analysis [70] comparing the use of 
proton pump inhibitors against either 
placebo or an H2-antagonist found a 
signiﬁ  cant reduction in rebleeding and 
the need for surgical intervention. Yet 
despite this clear beneﬁ  t, the trend in 
mortality was actually in the opposite 
direction. For studies of intravenous 
therapy, as is given to critically ill 
patients, the odds ratio for mortality 
was 1.22 (95% conﬁ  dence interval 
0.84–1.78).
Conclusions
It should be immediately acknowledged 
that most of the above ﬁ  ndings have 
been derived from relatively small 
patient studies or extrapolated from in 
vivo and in vitro laboratory studies. As 
with most aspects of medicine, there 
are contradictory results. Yet sufﬁ  cient 
data exist to suggest that the possibility 
of insidious harm should not be lightly 
dismissed. The above litany of problems 
should also not be used as a reason to 
abandon current practices, but instead 
to stimulate discussion, reﬁ  ne their use, 
and to encourage trials designed to 
conﬁ  rm or refute detriment. 
Our concern is that neither the 
inclination nor the funding will be 
generally available to revisit accepted 
dogma. We will thus have to rely on 
a slowly evolving approach, where 
new therapies are compared with 
conventional treatments, or where a 
media-highlighted concern propels a 
certain strategy into the spotlight. This 
was the case, for example, with the use 
of albumin for ﬂ  uid administration. 
A Cochrane meta-analysis suggested a 
4% increase in mortality with albumin 
over crystalloid solutions [70]. The 
subsequent prospective randomised 
trial of 6,997 patients revealed no 
overall difference in mortality; 
intriguingly, subset analysis suggested 
beneﬁ  t when used in sepsis but harm in 
head-injured patients [71].  
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